Post #4: Has the Fosun acquisition of India’s Gland Pharma taken a surprising turn?

Chinese enterprises and academia alike have long been closely watching China’s investment trends in India—and India’s governmental stance toward Chinese capital. Take, for example, Fosun’s proposed acquisition of the Indian pharmaceutical company Gland Pharma—a deal valued at over USD 1 billion. Last year, news emerged that the transaction had stalled at the highest levels of the Indian government; many domestic commentators linked this delay to the earlier Doklam standoff. Recently, however, according to an announcement by India’s Securities and Exchange Board of India (SEBI), Fosun has revised its investment plan to bypass governmental approval altogether—potentially allowing this massive deal to be finalized imminently, evoking the idiom “after darkness comes light.” Naturally, multiple factors are at play—not only Sino-Indian political relations, but also China’s heightened requirements for authenticity and value preservation in overseas investments, as well as India’s concerns about national industry security amid surging foreign capital inflows. A closer look reveals numerous intriguing nuances. Gland Pharma specializes in injectable drugs. Founded in 1978, it currently markets over 60 products in the United States and approximately 150 products across other countries—offering broad product coverage and substantial scale. Acquisition, as a rapid market-entry strategy, offers distinct advantages over greenfield projects. Beyond the multi-year timeline typically required for construction, commissioning, cost recovery, and eventual profitability, pharmaceutical projects face additional regulatory hurdles. Thus, acquiring equity in an established company—with full regulatory licenses, comprehensive product portfolios, mature distribution channels, and stable customer bases—is undeniably strategic. Fosun, well-versed in overseas investment, adopted precisely this approach. In 2016, Fosun initially planned to acquire 86% of Gland Pharma’s shares for USD 1.26 billion. Under India’s Companies Act, holding more than 75% of a company’s shares constitutes absolute control—a threshold higher than China’s “two-thirds or more” standard. Had India’s government approved Fosun’s 2016 proposal, Fosun would have gained absolute control over Gland Pharma. Whether Fosun originally intended a full acquisition—or what its initial target stake truly was—remains unclear to outsiders. Still, retaining partial ownership for Indian shareholders was undoubtedly prudent. Operating a mega-scale enterprise in India—a market vastly different from China’s—would likely prove fraught with challenges without local support. By preserving minority stakes for Indian shareholders and reserving board seats for them, Fosun could better leverage their local resources. Unfortunately, the original deal failed to secure timely approval from India’s Cabinet Committee on Economic Affairs (CCEA), leaving it suspended until now. But just days ago, SEBI disclosed that Fosun had reduced its proposed acquisition stake to 74%. Per India’s Consolidated FDI Policy for FY 2017–2018—officially released on August 31, 2017—acquisitions of up to 74% (i.e., falling short of absolute control) qualify for the automatic route, requiring no government approval for foreign investment entry (see India’s 2017–2018 Consolidated…

The Power Game in Pharma: Mergers, Acquisitions, and Deals Reshaping 2025

Mergers, acquisitions, and high-value collaborations are rapidly transforming the pharmaceutical industry. As drug R&D costs continue to surge and market competition intensifies, numerous pharmaceutical companies are leveraging transactions to access cutting-edge technologies—bolstering core competitiveness and securing advantageous positions in high-impact therapeutic areas. AdisInsight has meticulously compiled a special report titled “The Power Game in Pharma: Mergers, Acquisitions, and Deals Reshaping 2025,” profiling 20 landmark transactions and their strategic implications. This report helps pharmaceutical companies, professionals, and other stakeholders better grasp industry development directions and key trends—and understand how the sector will continue responding to global health challenges. Download the full report free of charge. The featured transactions highlight the industry’s strategic priorities: advancing precision medicine technologies (e.g., CryptoMap™ and Hybrozyme platforms), entering high-growth therapeutic areas—including rare diseases, neurodegenerative disorders, and oncology. These deals also reflect pharma’s growing emphasis on collaboration: large players such as Merck & Co. and AstraZeneca increasingly partner with agile biotech firms to access frontier innovations and accelerate pipeline development. In sum, the convergence of scientific advancement and strategic collaboration embodied in these 20 transactions underscores the industry’s deepening focus on innovation, precision medicine, and breakthrough therapies—and vividly illustrates the resilient, proactive character of a pharmaceutical sector undergoing profound transformation. Pharma M&A Watch Mergers and acquisitions in the pharmaceutical and biotechnology sectors constitute strategic initiatives enabling companies to accelerate new drug and medical technology development, integrate resources, expand market share—and thereby strengthen competitive advantage. Consequently, they play a pivotal role in shaping the industry’s landscape. In 2025, a wave of strategic acquisitions is actively reshaping the future of the pharmaceutical industry. While a few high-profile deals dominate headlines, others are gradually gaining traction—drawing close attention from investors and market analysts alike. Below is a brief overview of some notable 2025 acquisitions gaining momentum in the market. Spanning biotech breakthroughs, pipeline expansion, and market consolidation, these deals reflect evolving strategic priorities and competitive dynamics within the global pharmaceutical landscape. ・ Johnson & Johnson: Acquired CAPLYTA for treating psychiatric and neurodegenerative disorders. ・ GlaxoSmithKline: Acquired IDRX-42 for gastrointestinal cancers. ・ Bausch + Lomb: Acquired WB007 for ophthalmic diseases. ・ Vividion Therapeutics: Acquired small-molecule precision therapies for cancer and immune-mediated diseases. ・ Bristol Myers Squibb: Acquired cell therapies in oncology. ・ Lantheus Holdings: Acquired Alzheimer’s disease imaging technology. ・ Veralox Therapeutics: Acquired cGAS inhibitor compounds for oncology and dermatology. ・ Sun Pharmaceutical: Acquired Checkpoint Therapeutics to bolster its oncology portfolio. ・ AstraZeneca: Acquired cell therapies in oncology. ・ Jazz Pharmaceuticals: Acquired oncology products. ・ Roche: Acquired CAR-T cell therapies in oncology. ・ Merck: Acquired small-molecule therapies for cancer. ・ Bain Capital: Acquired multiple therapies for diverse diseases. ・ Dapeng Pharmaceutical: Acquired antibody-drug conjugates (ADCs) for cancer.

Anupam Rasayan completes acquisition of Bliss GVS Pharma

1 hour ago

Anupam Rasayan finalized the acquisition of Bliss GVS Pharma for $182.3 million, securing a controlling stake and entering the finished dosage formulations segment. This strategic move expands their global manufacturing footprint and strengthens access to pharmaceutical ingredients.

chemweek

2026-10-12

Anupam Rasayan completes acquisition of Bliss GVS Pharma

Anupam Rasayan completes acquisition of Bliss GVS Pharma

FAQ